摘要
目的评价依达拉奉联合巴曲酶和奥扎格雷治疗急性脑梗死(ACI)的疗效及安全性。方法 70例ACI患者随机分为治疗组(使用依达拉奉,34例)和对照组(不使用依达拉奉,36例),疗程14d。分别评价两组治疗前后美国国立卫生研究院卒中量表(NIHSS)评分和日常生活能力(ADL)评分,同时检测两组治疗前、治疗后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原降解产物(FDP)等。结果治疗14d,治疗组(88.24%)与对照组(52.78%)总有效率差异有统计学意义的显著性(P<0.01);两组NIHSS评分、ADL评分、PT和APTT值组间差异有统计学意义(P<0.05)。与治疗前相比,治疗14d两组FDP含量均明显降低(P<0.01)。不良反应发生率两组间差异无统计学意义(P>0.05)。结论依达拉奉联合巴曲酶和奥扎格雷治疗ACI疗效明显,安全可靠。
Objective To evaluate the efficacy and safety of edaravone combined with batroxobin and ozagrel in the treatment of acute cerebral infarction （ACI）. Methods Seventy patients of ACI were randomly divided into two groups： treatment group （edaravone, n=34） and control group （non-use of edaravone, n=36）. The scores of National Institute of Health Stroke Scale （NIHSS） and Activities of Daily Living Scale （ADL） were assessed before and after treatment. At the same time, the level of prothrombin time （PT）, activated partial thromboplastin time （APTT） and fibrinogen degradation product（FDP） were detected. Results＇ After 14 days treatment, total effective rate in the therapy group （88.24%） was higher than that in the control group （52.78%, P〈0.01）; the NIHSS score, ADL score, PT level and APTT level were different significantly between two groups （P〈0.05）. The level of FDP in two groups was decreased, and the difference was significant between before and after treatment （P〈0.01）. There was no significant difference in the rate of adverse reaction between two groups （P〉0.05）. Conclusion Edaravone combined with batroxoabin and ozagre is effective and safer in the treatment of ACI.
出处
《世界临床药物》
CAS
2010年第7期413-416,共4页
World Clinical Drug
基金
2008年"上海医院药学科研基金--临床药学专项"(2008-YY-0115)
